Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of its flu vaccines in China following concerns over declining potency identified during routine batch checks. According to FiercePharma.com, which cites an email from a Sanofi spokesperson, the suspension will affect supplies of both Vaxigrip and VaxigripTetra, potentially impacting the upcoming 2024-25 influenza season.
The halt in rollout was prompted by a quality control test that indicated “the efficacy could possibly be impacted before the end of the product’s shelf life for one of the antigens in the vaccine,” as stated in the email. Sanofi reassured that there are no concerns regarding the Good Manufacturing Practices (GMP) of either vaccine, characterizing the distribution pause as a precautionary measure to mitigate future risks. Importantly, as both vaccines are exclusively produced at Sanofi’s Shenzhen facility for the Chinese market, the decision does not extend to other regions.- Flcube.com
